Skip to main content

High-dose enoxaparin in the treatment of abdominal angiostrongyliasis in Swiss mice

  • A.S.S. Sandri (a1), R. Rodriguez (a2), M.M. Costa (a2), S.M. Porto (a2), D. Schwingel (a1) and M.I.B. Vieira (a1)...

Abdominal angiostrongyliasis (AA) is caused by Angiostrongylus costaricensis, which inhabits mesenteric arteries. There is no drug treatment for AA, and since intestinal infarction due to thrombi is one of the main complications of the disease, the use of anticoagulants may be a treatment option. Thus, we aimed to assess the effect of high doses of enoxaparin on the prevention of ischaemic intestinal lesions and on the survival of mice infected with A. costaricensis. Twenty-four mice were infected with L3 of A. costaricensis and divided equally into two groups: Group 1, control treated with placebo, and Group 2, treated daily with enoxaparin (2.5 mg/kg) for 50 days. All mice were subjected to necropsy and histological analysis. The results from gross and microscopic assessments showed no variation in the prevalence of lesions between the groups. An analysis was also performed among survivors and non-survivors, showing that animals that died often presented lesions, such as granulation tissue in the serosa, and intestinal infarction and adhesion. The mortality rate did not vary between the enoxaparin-treated and control groups. Thus, we showed that high doses of enoxaparin have no protective effect against AA, as the survival rates and lesions of mice did not vary between the treated and control groups. Considering that the use of prophylactic doses was also shown to be ineffective in a previous study, we do not recommend the use of enoxaparin for AA treatment.

Corresponding author
Author for correspondence: M.I.B. Vieira, E-mail:
Hide All
Andújar, MA, Matoses, CC, Rodríguez, LFJ and Navarro, RA (2016) Individualización posológica de enoxaparina en un obeso extremo mediante la monitorización del factor anti-Xa. Farmacia Hospitalaria 40, 5859.
de Azevedo, GV, Rodriguez, R, Porto, SM, Graeff-Teixeira, C and Fornari, F (2011) Elimination of Angiostrongylus costaricensis larvae in feces from experimentally infected Swiss mice: circadian rhythm and correlation with survival. Parasitology Research 108, 537540.
Fante, CA, Dieterish, S and Rodriguez, R (2008) Betametasona e extrato aquoso de Arctium lappa no tratamento da angiostrongilíase. Revista da Sociedade Brasileira de Medicina Tropical 41, 654657.
Graeff-Teixeira, C, Camillo-Coura, L and Lenzi, HL (1991) Histopathological criteria for the diagnosis of abdominal angiostrongyliasis. Parasitology Research 77, 606611.
Harter, K, Levine, M and Henderson, SO (2015) Anticoagulation drug therapy: a review. Western Journal of Emergency Medicine 16, 1117.
Ishii, A, Terada, M, Fujiu, Y and Sano, M (1989) In vivo efficacy of levamisole against larval stages of Angiostrongylus cantonensis and A. costaricensis. Southeast Asian Journal of Tropical Medicine and Public Health 20, 109117.
Li, D-W, Lee, IS, Sim, J-S, Toida, T, Linhardt, RJ and Kim, YS (2004) Long duration of anticoagulant activity and protective effects of acharan sulfate in vivo. Thrombosis Research 113, 6773.
Mentz, MB and Graeff-Teixeira, C (2003) Drug trials for treatment of human angiostrongyliasis. Revista do Instituto de Medicina Tropical de São Paulo 45, 179184.
Morera, P and Bontempo, I (1985) Acción de algunos antihelminticos sobre Angiostrongylus costaricensis. Revista Médica del Hospital Nacional de Niños Dr. Carlos Saenz Herrera 20, 165174.
Morera, P and Céspedes, R (1971) Angiostrongylus costaricensis n. sp. (Nematoda: Metastrongyloidea), a new lungworm occurring in man in Costa Rica. Revista de Biología Tropical 18, 17.
Mousa, SA (2004) Heparin and low molecular weight heparin in thrombosis, cancer, and inflammatory diseases. pp. 3548 In Mousa, S.A. (Ed.) Anticoagulants, Antiplatelets, and Thrombolytics. Totowa, New Jersey, Humana press.
Rafaluk, C, Gildenhard, M, Mitschke, A, Telschow, A, Schulenburg, H and Joop, G (2015) Rapid evolution of virulence leading to host extinction under host–parasite coevolution. BMC Evolutionary Biology 15, 112.
Rodriguez, R, Porto, SM, dos Santos Ferrari, R, Marcolan, AM, da Silva, ACA, Graeff-Teixeira, C and Fornari, F (2011) Outcomes in mice with abdominal angiostrongyliasis treated with enoxaparin. Parasitology Research 109, 787792.
Silvain, J, Beygui, F, Barthélémy, O, Pollack, C, Cohen, M, Zeymer, U, Huber, K, Goldstein, P, Cayla, G and Collet, J-P (2012) Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. British Medical Journal 344, e553.
Terada, M, Rodriguez, O, Dharejo, A, Ishii, A and Sano, M (1986) Studies on chemotherapy of parasitic helminths (XXVI). Comparative in vitro effects of various anthelmintics on the motility of Angiostrongylus costaricensis and Angiostrongylus cantonensis. Japanese Journal of Parasitology 35, 365367.
Waisberg, J, Corsi, CE, Rebelo, MV, Vieira, VTT, Bromberg, SH, dos Santos, PA and Monteiro, R (1999) Jejunal perforation caused by abdominal angiostrongyliasis. Revista do Instituto de Medicina Tropical de São Paulo 41, 325328.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Journal of Helminthology
  • ISSN: 0022-149X
  • EISSN: 1475-2697
  • URL: /core/journals/journal-of-helminthology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed